Louai Labanieh, PhD
About Me
Dr. Labanieh is an Assistant Professor in the Icahn Genomics Institute (IGI) and the Precision Immunology Institute (PrIISM) at Mount Sinai School of Medicine. As a bioengineer with expertise in synthetic biology, immunoengineering, and T-cell biology, Dr. Labanieh is developing next-generation high performance platform technologies to address the most pressing challenges for cell therapies for cancer. He developed SNIP-CAR, a drug-regulated CAR platform that enhances the safety and efficacy of CAR-T cells. The findings from his work credentialed this platform as best-in-class and laid the foundational preclinical studies to support a phase I clinical trial of the SNIP CAR platform in relapsed/refractory solid cancers at Stanford University School of Medicine. He has also developed technologies for drug-regulated control over cytokine signaling in engineered T-cells as well as a platform for purification of multi-engineered, sophisticated cell therapies. He has worked collaboratively to create logic-gated T-cells, injectable hydrogels for delivering cell therapies and cytokines, and technologies for imaging cell therapies in vivo. Dr. Labanieh is a co-inventor of 13 technologies spanning the fields of cell therapy, diagnostics, and high-throughput drug discovery. These technologies have been licensed to five biotechnology companies, including CARGO Therapeutics, a publicly traded and clinical stage CAR-T startup that Dr. Labanieh co-founded. The Labanieh Lab focuses on the development of biotechnologies that allow for precision genetic engineering and control of cell functions in vivo, with a particular focus on platforms that enhance the efficacy and safety of cell and gene therapies for cancer and other diseases.
Language
Position
Research Topics
Anti-Tumor Therapy, Autoimmunity, Biomechanics/Bioengineering, Breast Cancer, Cancer, Gene Therapy, Gene editing, Genetics, Immunology, Lymphocytes, Pediatrics, T Cells, Translational Research
Multi-Disciplinary Training Areas
Artificial Intelligence and Emerging Technologies in Medicine [AIET], Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT), Genetics and Genomic Sciences [GGS], Immunology [IMM]
About Me
Dr. Labanieh is an Assistant Professor in the Icahn Genomics Institute (IGI) and the Precision Immunology Institute (PrIISM) at Mount Sinai School of Medicine. As a bioengineer with expertise in synthetic biology, immunoengineering, and T-cell biology, Dr. Labanieh is developing next-generation high performance platform technologies to address the most pressing challenges for cell therapies for cancer. He developed SNIP-CAR, a drug-regulated CAR platform that enhances the safety and efficacy of CAR-T cells. The findings from his work credentialed this platform as best-in-class and laid the foundational preclinical studies to support a phase I clinical trial of the SNIP CAR platform in relapsed/refractory solid cancers at Stanford University School of Medicine. He has also developed technologies for drug-regulated control over cytokine signaling in engineered T-cells as well as a platform for purification of multi-engineered, sophisticated cell therapies. He has worked collaboratively to create logic-gated T-cells, injectable hydrogels for delivering cell therapies and cytokines, and technologies for imaging cell therapies in vivo. Dr. Labanieh is a co-inventor of 13 technologies spanning the fields of cell therapy, diagnostics, and high-throughput drug discovery. These technologies have been licensed to five biotechnology companies, including CARGO Therapeutics, a publicly traded and clinical stage CAR-T startup that Dr. Labanieh co-founded. The Labanieh Lab focuses on the development of biotechnologies that allow for precision genetic engineering and control of cell functions in vivo, with a particular focus on platforms that enhance the efficacy and safety of cell and gene therapies for cancer and other diseases.
Language
Position
Research Topics
Anti-Tumor Therapy, Autoimmunity, Biomechanics/Bioengineering, Breast Cancer, Cancer, Gene Therapy, Gene editing, Genetics, Immunology, Lymphocytes, Pediatrics, T Cells, Translational Research
Multi-Disciplinary Training Areas
Artificial Intelligence and Emerging Technologies in Medicine [AIET], Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT), Genetics and Genomic Sciences [GGS], Immunology [IMM]
